S. Wind

发表

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

Glen R. Wunderlich, Viktoria Moschetti, M. Desch, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition

A. Shah, H. Schmidt, A. Shah, 2010, Hypertension.

Comparative pharmacology of chemically distinct NADPH oxidase inhibitors

H. Schmidt, K. Wingler, S. Wind, 2010, British journal of pharmacology.

Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats

S. Wind, A. Taei, 2010 .

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

Holger Rosenbrock, Glen R. Wunderlich, S. Ramael, 2018, Clinical and translational science.

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

Glen R. Wunderlich, T. Chan, M. Goettel, 2021, European journal of drug metabolism and pharmacokinetics.

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Glen R. Wunderlich, H. Schmitt, Viktoria Moschetti, 2018, Clinical Drug Investigation.

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

A. Halabi, A. Weber, S. Wiebe, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.

R. Kaiser, R. Doebele, D. Camidge, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

M. Uttenreuther-Fischer, A. Halabi, Rainer-Georg Goeldner, 2014, Cancer Chemotherapy and Pharmacology.

No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone

K. Hohl, L. Richeldi, T. Maher, 2018, European Respiratory Journal.

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

A. Staab, U. Schmid, M. Freiwald, 2014, Cancer Chemotherapy and Pharmacology.

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

M. Kreuter, M. Vonk, S. Wind, 2021, European journal of drug metabolism and pharmacokinetics.

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

Rainer-Georg Goeldner, P. Stopfer, S. Wind, 2013, Clinical Pharmacokinetics.

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

R. Busse, R. Brandes, H. Schmidt, 2008, Hypertension.

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

T. Ebner, U. Schmid, M. Freiwald, 2019, Clinical Pharmacokinetics.

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.

W. Mason, D. Eisenstat, S. Phuphanich, 2014, Neuro-oncology.

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

M. Beckmann, P. Fasching, P. Neven, 2012, Breast Cancer Research and Treatment.

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.

J. Machiels, S. Rottey, J. Vermorken, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel.

J. Spicer, S. Rudman, J. D. de Bono, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

T. Ebner, M. Freiwald, P. Stopfer, 2016, Clinical Pharmacokinetics.

A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole

M. Uttenreuther-Fischer, F. Joly, J. Gligorov, 2016, SpringerPlus.

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

P. LoRusso, M. Gordon, S. Wind, 2015, Future oncology.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Y Huang, L. Sequist, K. O'Byrne, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Tamas Hickish, Pamela Munster, Eric P. Winer, 2012, Breast Cancer Research and Treatment.

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

T. Giessmann, P. Stopfer, S. Wind, 2014, Clinical Drug Investigation.

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

T. Chan, M. Goettel, M. Desch, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer

D. Camidge, G. Otterson, A. Traynor, 2022 .

Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors.

J. Soria, M. Uttenreuther-Fischer, C. Massard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Viktoria Moschetti, M. Desch, Sophia Goetz, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

J. Machiels, J. Vermorken, E. Ehrnrooth, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates

F. Müller, K. Hohl, T. Chan, 2023, Journal of clinical psychopharmacology.

Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)

D. Carbone, K. O'Byrne, M. Ahn, 2016 .